Hypogonadism - male
Methodology & AI Transparency ⓘ
Hypogonadism - male Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Physicians managing Hypogonadism - male (E29.1; Men's Health, Testosterone & Sexual Function) utilize fertility-preserving SERM/gonadotropin options in Hypogonadism - male (E29.1: vs.
- 2 Real-world patient consensus: Mapped to Men's Health, Testosterone & Sexual Function under ICD-10-CM E29.1 for Hypogonadism - male clinical workups.
- 3 Typical cash cost range: Workup highlights for Hypogonadism - male (E29.1): fertility-preserving SERM/gonadotropin options in Hypogonadism - male (E29.1: vs. exogenous TRT).
- 4 Top reported side effects / signs: Follow-up benchmark in Hypogonadism - male: maintaining Hematocrit & Total in Hypogonadism - male (E29.1: PSA) within Hct < 50%; age-appropriate PSA (E29.1).
Ask our AI Specialists anything about Hypogonadism - male
What Is Hypogonadism - male?
Physicians managing Hypogonadism - male (E29.1; Men's Health, Testosterone & Sexual Function) utilize fertility-preserving SERM/gonadotropin options in Hypogonadism - male (E29.1: vs. exogenous TRT) and objective Hematocrit & Total in Hypogonadism - male (E29.1: PSA) targets (Hct < 50%; age-appropriate PSA (E29.1)) to prevent progression and functional morbidity.
Pathophysiology, Underlying Causes & Clinical Presentation
Underlying Hypogonadism - male (code E29.1) is primary testicular Leydig in Hypogonadism - male (E29.1: cell insufficiency or), which Men's Health, Testosterone & Sexual Function clinicians address while surveilling Hematocrit & Total in Hypogonadism - male (E29.1: PSA) (Hct < 50%; age-appropriate PSA (E29.1)).
Common Symptoms & Clinical Signs
- • Presentation of Hypogonadism - male (E29.1): loss of lean in Hypogonadism - male (E29.1: muscle recovery, rising)
- • Secondary Hypogonadism - male clinical sign: blunted motivation, depressed in Hypogonadism - male (E29.1: mood, or declining)
- • Symptom flares in Hypogonadism - male correlating with Hematocrit & Total in Hypogonadism - male (E29.1: PSA) deviation outside Hct < 50%; age-appropriate PSA (E29.1)
- • Functional men's health & trt impact requiring fertility-preserving SERM/gonadotropin options in Hypogonadism - male (E29.1: vs. exogenous TRT) evaluation (E29.1)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Hypogonadism - male Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | E29.1 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Men's Health, Testosterone & Sexual Function | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: Hematocrit & Total in Hypogonadism - male (E29.1: PSA) | Hct < 50%; age-appropriate PSA (E29.1) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Ultrasensitive Estradiol & in Hypogonadism - male (E29.1: ApoB) | E2 20–38 pg/mL; ApoB < 80 mg/dL (E29.1) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Morning Total & in Hypogonadism - male (E29.1: Free Testosterone (2x) | Total 500–900 ng/dL; Free 110–210 pg/mL (E29.1) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Hypogonadism - male
Treatment selection for Hypogonadism - male depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Hypogonadism - male)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Testosterone Therapy for Late-Onset Hypogonadism Improves Erectile: What a 1,458-Participant Study Found TTh achieved a significant improvement in the IIEF-EFD score of hypogonadal men compared with placebo, especially in those who received testosterone gel, were treated for over 30 weeks, and had no comorbidities. Urologia internationalis • 2022-01-15 • Meta-Analysis | N = 1,458 | 99/100 | PMID 34856556 ↗ |
| New Insights on Efficacy of testosterone replacement therapy for treating metabolic disturbances: What a 1,373-Participant Study Found This study demonstrated greater improvement in metabolic profiles for patients given TRT versus placebo. International urology and nephrology • 2021-09-15 • Meta-Analysis | N = 1,373 | 99/100 | PMID 34089171 ↗ |
| New Insights on Prostate Safety Events During Testosterone Replacement Therapy in Men With: What a 5,246-Participant Study Found A total of 5204 men (mean [SD] age, 63.3 [7.9] years) were analyzed. JAMA network open • 2023-12-01 • Randomized Controlled Trial | N = 5,246 | 96/100 | PMID 38150256 ↗ |
| New Insights on Testosterone Treatment and Fractures in Men with: What a 5,204-Participant Study Found Among middle-aged and older men with hypogonadism, testosterone treatment did not result in a lower incidence of clinical fracture than placebo. The New England journal of medicine • 2024-01-18 • Randomized Controlled Trial | N = 5,204 | 96/100 | PMID 38231621 ↗ |
| New Insights on Efficacy of Testosterone Replacement Therapy in Correcting Anemia in Men With: What a 5,204-Participant Study Found A total of 5204 men were included, 815 with anemia (mean [SD] age, 64.8 [7.7] years; 247 Black [30.3%], 544 White [66.7%], 24 other [2.9%]) and 4379 without anemia (mean [SD] age, 63.0 [7.9] years; 629 Black [14.4%], 3603... JAMA network open • 2023-10-02 • Randomized Controlled Trial | N = 5,204 | 96/100 | PMID 37889486 ↗ |
Hypogonadism - male Patient Community & “People Like Me” Threads
Filter Hypogonadism - male community threads and patient logs by age, biological sex, dosage, and treatment duration.